Lilly’s bamlanivimab and etesevimab belong to a class of drugs called monoclonal antibody treatments, which mimic natural antibodies the body generates to fight infection.
This is the latest antibody treatment to earn such a review in the region and follows the European Medicines Agency’s (EMA) evaluation of drugs from South Korea’s Celltrion and U.S.-based Regeneron.
The rolling reviews are aimed at speeding up the approval process by allowing researchers to submit findings in real-time before final trial data is available.
Vir Biotechnology and Britain’s GSK plan to seek emergency use authorization for their experimental antibody therapy after interim data, the companies said on Thursday.
EMA said it was yet to evaluate the full dataset, adding it was too early to draw any conclusions regarding the benefit-risk balance of Lilly’s medicines.
It said the decision to start the review was based on preliminary results from two studies, one testing the ability of the antibodies to treat patients when combined and the other when bamlanivimab is used as a standalone.
So far, vaccines from Pfizer/BioNTech,, Moderna and AstraZeneca/Oxford have been approved in the region, with the verdict on J&J’s single-shot vaccine is expected later in the day.
(Reporting by Muvija M and Indranil Sarkar in Bengaluru; Editing by Sriraj Kalluvila)
Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]